{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:05Z","timestamp":1793058905926,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s10557-005-5686-z","type":"journal-article","created":{"date-parts":[[2006,2,2]],"date-time":"2006-02-02T00:16:03Z","timestamp":1138839363000},"page":"403-414","source":"Crossref","is-referenced-by-count":1005,"title":["Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients \u2014The PRIMO Study"],"prefix":"10.1007","volume":"19","author":[{"given":"Eric","family":"Bruckert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Hayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Dejager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,31]]},"reference":[{"issue":"8934","key":"5686_CR1","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Investigators","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383\u20131389.","journal-title":"Lancet"},{"issue":"19","key":"5686_CR2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349\u20131357.","journal-title":"N Engl J Med"},{"issue":"7","key":"5686_CR3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","volume":"74","author":"RH Bradford","year":"1994","unstructured":"Bradford RH, Shear CL, Chremos AN, et\u00a0al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994;74(7):667\u2013673.","journal-title":"Am J Cardiol"},{"issue":"20","key":"5686_CR4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et\u00a0al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615\u20131622.","journal-title":"JAMA"},{"issue":"14","key":"5686_CR5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et\u00a0al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001\u20131009.","journal-title":"N Engl J Med"},{"issue":"20","key":"5686_CR6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et\u00a0al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301\u20131307.","journal-title":"N Engl J Med"},{"issue":"14","key":"5686_CR7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0002-9149(93)90858-A","volume":"72","author":"The Pravastatin Multinational Study Group for Cardiac Risk Patients","year":"1993","unstructured":"The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8\u00a0mmol\/liter (200 to 300\u00a0mg\/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72(14):1031\u20131037.","journal-title":"Am J Cardiol"},{"issue":"1","key":"5686_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9150(99)00294-4","volume":"149","author":"RG Bakker-Arkema","year":"2000","unstructured":"Bakker-Arkema RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 2000;149(1):123\u2013129.","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"5686_CR9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0021-9150(96)06052-2","volume":"130","author":"S Bertolini","year":"1997","unstructured":"Bertolini S, Bon GB, Campbell LM, et\u00a0al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130(1\u20132):191\u2013197.","journal-title":"Atherosclerosis"},{"issue":"5","key":"5686_CR10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","volume":"15","author":"JW Nawrocki","year":"1995","unstructured":"Nawrocki JW, Weiss SR, Davidson MH, et\u00a0al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15(5):678\u2013682.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3\u20134","key":"5686_CR11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000176682","volume":"85","author":"E Steinhagen-Thiessen","year":"1994","unstructured":"Steinhagen-Thiessen E. Comparative efficacy and tolerability of 5 and 10\u00a0mg simvastatin and 10\u00a0mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group. Cardiology 1994;85(3\u20134):244\u2013254.","journal-title":"Cardiology"},{"key":"5686_CR12","doi-asserted-by":"crossref","unstructured":"Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346(7):539\u2013540.","DOI":"10.1056\/NEJM200202143460721"},{"issue":"6","key":"5686_CR13","first-page":"541","volume":"48","author":"LJ Lambrecht","year":"1993","unstructured":"Lambrecht LJ, Malini PL. Efficacy and tolerability of simvastatin 20\u00a0mg vs pravastatin 20\u00a0mg in patients with primary hypercholesterolemia. European Study Group. Acta Cardiol 1993;48(6):541\u2013554.","journal-title":"Acta Cardiol"},{"issue":"6","key":"5686_CR14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0895-4356(99)00019-0","volume":"52","author":"E Bruckert","year":"1999","unstructured":"Bruckert E, Simonetta C, Giral P. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. J Clin Epidemiol 1999;52(6):589\u2013594.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"5686_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9149(97)00280-4","volume":"80","author":"A Dart","year":"1997","unstructured":"Dart A, Jerums G, Nicholson G, et\u00a0al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80(1):39\u201344.","journal-title":"Am J Cardiol"},{"issue":"14","key":"5686_CR16","doi-asserted-by":"crossref","first-page":"18D","DOI":"10.1016\/0002-9149(94)90628-9","volume":"73","author":"LA Jokubaitis","year":"1994","unstructured":"Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol 1994;73(14):18D\u201324D.","journal-title":"Am J Cardiol"},{"issue":"7","key":"5686_CR17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/0003-4819-137-7-200210010-00015","volume":"137","author":"SM Grundy","year":"2002","unstructured":"Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med 2002;137(7):617\u2013618.","journal-title":"Ann Intern Med"},{"issue":"2","key":"5686_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00005344-200208000-00001","volume":"40","author":"H Sinzinger","year":"2002","unstructured":"Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol 2002;40(2):163\u2013171.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"5686_CR19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","volume":"163","author":"CM Ballantyne","year":"2003","unstructured":"Ballantyne CM, Corsini A, Davidson MH, et\u00a0al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163(5):553\u2013564.","journal-title":"Arch Intern Med"},{"key":"5686_CR20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"JA De Lemos","year":"2004","unstructured":"De Lemos JA, Blazing MA, Wiviott SD, et\u00a0al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial. JAMA 2004;292:1307\u20131316.","journal-title":"JAMA"},{"issue":"2","key":"5686_CR21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et\u00a0al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227\u2013239.","journal-title":"Circulation"},{"issue":"5\u20136","key":"5686_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","volume":"17","author":"S Franc","year":"2003","unstructured":"Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003;17(5\u20136):459\u2013465.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"5686_CR23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","volume":"40","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40(3):567\u2013572.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"5686_CR24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681\u20131690.","journal-title":"JAMA"},{"issue":"1","key":"5686_CR25","first-page":"1","volume":"23","author":"Adverse Drug Reactions Advisory Committee (ADRAC)","year":"2004","unstructured":"Adverse Drug Reactions Advisory Committee (ADRAC). Risk factors for myopathy and rhabdomyolysis with the statins. Aust Adv Drug Reactions Bull 2004;23(1):1\u20132.","journal-title":"Aust Adv Drug Reactions Bull"},{"issue":"10","key":"5686_CR26","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","volume":"46","author":"PD Thompson","year":"1997","unstructured":"Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46(10):1206\u20131210.","journal-title":"Metabolism"},{"issue":"5","key":"5686_CR27","first-page":"907","volume":"65","author":"JM Sauret","year":"2002","unstructured":"Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician 2002;65(5):907\u2013912.","journal-title":"Am Fam Physician"},{"issue":"7404","key":"5686_CR28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326(7404):1423.","journal-title":"BMJ"},{"issue":"2","key":"5686_CR29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0002-9149(01)02209-3","volume":"89","author":"R Benghozi","year":"2002","unstructured":"Benghozi R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002;89(2):231\u2013233.","journal-title":"Am J Cardiol"},{"issue":"9","key":"5686_CR30","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1345\/aph.10228","volume":"35","author":"MA Omar","year":"2001","unstructured":"Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35(9):1096\u20131107.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"5686_CR31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0090-9556(24)14919-7","volume":"27","author":"V Fischer","year":"1999","unstructured":"Fischer V, Johanson L, Heitz F, et\u00a0al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999;27(3):410\u2013416.","journal-title":"Drug Metab Dispos"},{"issue":"9326","key":"5686_CR32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"MRC\/BHF Heart Protection Study Group","year":"2002","unstructured":"MRC\/BHF Heart Protection Study Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"4","key":"5686_CR33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","volume":"288","author":"CA Jackevicius","year":"2002","unstructured":"Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288(4):462\u2013467.","journal-title":"JAMA"},{"issue":"2","key":"5686_CR34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF03259907","volume":"4","author":"C Koppel","year":"1989","unstructured":"Koppel C. Clinical features, pathogenesis and management of drug-induced rhabdomyolysis. Med Toxicol Adverse Drug Exp 1989;4(2):108\u2013126.","journal-title":"Med Toxicol Adverse Drug Exp"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-5686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-005-5686-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-5686-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:45:35Z","timestamp":1736264735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-005-5686-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["5686"],"URL":"https:\/\/doi.org\/10.1007\/s10557-005-5686-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}